The Future of Safety
How automation and machine learning are transforming Pharmacovigilance
White Paper
Mar 28, 2019

Introduction

Despite rapid advances in technology, pharmacovigilance (PV) units still handle the majority of adverse event and safety information data collection and processing through manual efforts. Once the data is captured, it is often stored in siloed databases making it difficult if not impossible to aggregate and analyze in meaningful ways.

According to the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), the amount of adverse event reporting is increasing by more than 15 percent annually. Adding to this complexity, the number and variety of data sources PV units are expected to review is growing exponentially, making it increasingly difficult for PV professionals to keep up.

Many of these data sources are unstructured in nature where information has to be culled from narratives rather than directly lifted from forms and reports. These unstructured sources include emails, social media posts, journal articles, audio files, and handwritten documents, some of which require language translation prior to extracting relevant details.

The deluge of new data, increasing requirements from regulators, and declining PV budgets are forcing the PV community to seek new solutions to improve the access, timeliness and cost-effectiveness of safety data management. 

 

Download to Read More
Related Solutions
Integrated Global Compliance

Meet the challenge of changing stakeholder demands and increasing cost constraints with IQVIA's integrated technology services and analytics-driven offerings.

You may also be interested in
Contact Us
Contact Us
Contact Us

Email Us

Get in touch today to discover the right solutions for you.

Call Us

We are pleased to speak with you during our standard business hours.

U.S. Toll-Free only
+1 866 267 4479

For international call please find a number in our toll-free list.